The estimated Net Worth of Nadim Ahmed is at least 5.49 百万$ dollars as of 26 December 2023. Mr. Ahmed owns over 4,272 units of Bristol-Myers Squibb Co stock worth over 5,420,215$ and over the last 6 years he sold BMY stock worth over 69,597$. In addition, he makes 0$ as Executive Vice President and President - Hematology at Bristol-Myers Squibb Co.
Nadim has made over 16 trades of the Bristol-Myers Squibb Co stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 4,272 units of BMY stock worth 39,473$ on 26 December 2023.
The largest trade he's ever made was exercising 17,204 units of Bristol-Myers Squibb Co stock on 1 March 2020 worth over 835,942$. On average, Nadim trades about 2,079 units every 52 days since 2018. As of 26 December 2023 he still owns at least 111,550 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Mr. Ahmed stock trades at the bottom of the page.
Nadim Ahmed serves as Executive Vice President and President - Hematology of the Company. 2014 to 2016 – Corporate Vice President, U.S. Commercial, Celgene 2016 to 2017 – Senior Vice President Worldwide Markets, Celgene 2017 to 2019 – Executive Vice President/President Hematology/Oncology, Celgene 2019 to present – Executive Vice President and President, Hematology
Nadim Ahmed is 52, he's been the Executive Vice President and President - Hematology of Bristol-Myers Squibb Co since 2019. There are 28 older and 7 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
Nadim's mailing address filed with the SEC is C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 16 years, insiders at Bristol-Myers Squibb Co have traded over 318,151,721$ worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth 6,601,565$ . The most active insiders traders include Lamberto Andreotti、James M Cornelius、Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of 1,682,720$. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth 51,554$.
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include: